{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T10:46:23Z","timestamp":1784630783915,"version":"3.55.0"},"reference-count":174,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T00:00:00Z","timestamp":1778889600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100014461","name":"NIHR Biomedical Research Centre, Royal Marsden NHS Foundation Trust\/Institute of Cancer Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014461","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Affective Disorders"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.jad.2026.121970","type":"journal-article","created":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T22:16:17Z","timestamp":1778969777000},"page":"121970","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Interdisciplinary, Delphi-driven consensus guidelines on the use of intravenous ketamine infusions for depressive disorders from the American Society of Ketamine Physicians, Psychotherapists, and Practitioners (ASKP3)"],"prefix":"10.1016","volume":"411","author":[{"given":"David S.","family":"Mathai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madeleine","family":"Cluck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amna M.","family":"Aslam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin","family":"Amato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arsalan","family":"Azam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Banov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen A.","family":"Barrett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carl J.","family":"Bonnett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Feifel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Grundmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H. Samuel","family":"Ko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rupert","family":"McShane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandhya","family":"Prashad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatiana","family":"Santini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lowan H.","family":"Stewart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Sullivan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefany D.","family":"Wolfsohn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jill O.","family":"Robinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy L.","family":"McGuire","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L. Alison","family":"McInnes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jad.2026.121970_bb0005","doi-asserted-by":"crossref","first-page":"85","DOI":"10.4103\/2229-3485.128028","article-title":"Evaluation the effects of adding ketamine to morphine in intravenous patient-controlled analgesia after orthopedic surgery","volume":"5","author":"Akhavanakbari","year":"2014","journal-title":"Perspect. Clin. Res."},{"key":"10.1016\/j.jad.2026.121970_bb0010","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.jpsychires.2022.04.037","article-title":"Real-world effectiveness of ketamine in treatment-resistant depression: a systematic review & meta-analysis","volume":"151","author":"Alnefeesi","year":"2022","journal-title":"J. Psychiatr. Res."},{"key":"10.1016\/j.jad.2026.121970_bb0015","author":"American Medical Association"},{"key":"10.1016\/j.jad.2026.121970_bb0020","series-title":"Diagnostic and Statistical Manual of Mental Disorders: DSM-5-TR","author":"American Psychiatric Association","year":"2022"},{"key":"10.1016\/j.jad.2026.121970_bb0025","author":"American Society of Anesthesiologists"},{"key":"10.1016\/j.jad.2026.121970_bb0030","author":"American Society of Anesthesiologists"},{"key":"10.1016\/j.jad.2026.121970_bb0035","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.1056\/NEJMoa2302399","article-title":"Ketamine versus ECT for nonpsychotic treatment-resistant major depression","volume":"388","author":"Anand","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jad.2026.121970_bb0040","first-page":"844","article-title":"The antidepressant effect of ketamine is dampened by concomitant benzodiazepine medication","volume":"11","author":"Andrashko","year":"2020","journal-title":"Front. Psychol."},{"key":"10.1016\/j.jad.2026.121970_bb0045","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/j.jad.2020.09.071","article-title":"Comparative efficacy of racemic ketamine and esketamine for depression: a systematic review and meta-analysis","volume":"278","author":"Bahji","year":"2021","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.jad.2026.121970_bb0050","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1080\/14740338.2022.2047928","article-title":"Efficacy and safety of racemic ketamine and ESKETAMINE for depression: a systematic review and META-analysis","volume":"21","author":"Bahji","year":"2022","journal-title":"Expert Opin. Drug Saf."},{"key":"10.1016\/j.jad.2026.121970_bb0055","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.psc.2023.02.001","article-title":"The individual and societal burden of treatment-resistant depression: an overview","volume":"46","author":"Baig-Ward","year":"2023","journal-title":"Psychiatr. Clin. North Am."},{"key":"10.1016\/j.jad.2026.121970_bb0060","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyg.2022.824077","article-title":"Psychedelic integration: an analysis of the concept and its practice","volume":"13","author":"Bathje","year":"2022","journal-title":"Front. Psychol."},{"key":"10.1016\/j.jad.2026.121970_bb0065","first-page":"1","article-title":"J&j\u2019s Spravato hit $1B in revenue in 2024 [WWW document]","author":"Bayer","year":"2025","journal-title":"Endpoints News."},{"key":"10.1016\/j.jad.2026.121970_bb0070","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1177\/00048674211039166","article-title":"Ketamine treatment for depression: a model of care","volume":"55","author":"Bayes","year":"2021","journal-title":"Aust. N. Z. J. Psychiatry"},{"key":"10.1016\/j.jad.2026.121970_bb0075","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.jad.2022.04.020","article-title":"The ketamine side effect tool (KSET): a comprehensive measurement-based safety tool for ketamine treatment in psychiatry","volume":"308","author":"Bayes","year":"2022","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.jad.2026.121970_bb0080","doi-asserted-by":"crossref","DOI":"10.1016\/j.psychres.2024.116334","article-title":"Safety outcomes of ketamine for treatment-resistant depression in clinical settings and development of the ketamine side effect tool-revised (KSET-R)","volume":"344","author":"Bayes","year":"2025","journal-title":"Psychiatry Res."},{"key":"10.1016\/j.jad.2026.121970_bb0085","doi-asserted-by":"crossref","DOI":"10.1192\/bjo.2023.577","article-title":"Multidisciplinary development of guidelines for ketamine treatment for treatment-resistant major depression disorder for use by adult specialist mental health services in New Zealand","volume":"9","author":"Beaglehole","year":"2023","journal-title":"BJPsych Open"},{"key":"10.1016\/j.jad.2026.121970_bb0090","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.4693","article-title":"Association of Ketamine with Psychiatric Symptoms and Implications for its therapeutic use and for understanding schizophrenia: a systematic review and Meta-analysis","volume":"3","author":"Beck","year":"2020","journal-title":"JAMA Netw. Open"},{"key":"10.1016\/j.jad.2026.121970_bb0095","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/S0006-3223(99)00230-9","article-title":"Antidepressant effects of ketamine in depressed patients","volume":"47","author":"Berman","year":"2000","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.jad.2026.121970_bb0100","doi-asserted-by":"crossref","DOI":"10.4045\/tidsskr.25.0045","article-title":"Ketamine in treatment-resistant depression","author":"Berthold-Losleben","year":"2025","journal-title":"Tidsskr. Nor. Laegeforen."},{"key":"10.1016\/j.jad.2026.121970_bb0105","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1007\/s40263-021-00846-5","article-title":"Prevention and Management of Common Adverse Effects of ketamine and Esketamine in patients with mood disorders","volume":"35","author":"Ceban","year":"2021","journal-title":"CNS Drugs"},{"key":"10.1016\/j.jad.2026.121970_bb0110","doi-asserted-by":"crossref","first-page":"587","DOI":"10.2147\/NDT.S401032","article-title":"Acute effects of intravenous sub-anesthetic doses of ketamine and intranasal inhaled Esketamine on suicidal ideation: a systematic review and meta-analysis","volume":"19","author":"Chen","year":"2023","journal-title":"Neuropsychiatr. Dis. Treat."},{"key":"10.1016\/j.jad.2026.121970_bb0115","article-title":"A higher dose (0.8 mg\/kg) of ketamine infusion for treatment-resistant depression: an open-label study in Taiwan","volume":"34","author":"Chen","year":"2020","journal-title":"Taiwan. J. Psychiatry"},{"key":"10.1016\/j.jad.2026.121970_bb0120","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1007\/s00213-021-05825-8","article-title":"Efficacy of ketamine for major depressive episodes at 2, 4, and 6-weeks post-treatment: a meta-analysis","volume":"238","author":"Conley","year":"2021","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.jad.2026.121970_bb0125","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.jad.2019.11.086","article-title":"Efficacy and safety of adjunctive therapy using esketamine or racemic ketamine for adult treatment-resistant depression: a randomized, double-blind, non-inferiority study","volume":"264","author":"Correia-Melo","year":"2020","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.jad.2026.121970_bb0130","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1177\/0004867416631828","article-title":"Ketamine augmentation for outpatients with treatment-resistant depression: preliminary evidence for two-step intravenous dose escalation","volume":"51","author":"Cusin","year":"2017","journal-title":"Aust. N. Z. J. Psychiatry"},{"key":"10.1016\/j.jad.2026.121970_bb0135","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/s44184-024-00091-w","article-title":"Meta-correlation of the effect of ketamine and psilocybin induced subjective effects on therapeutic outcome","volume":"3","author":"Dahan","year":"2024","journal-title":"npj Mental Health Res"},{"key":"10.1016\/j.jad.2026.121970_bb0140","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1001\/jamapsychiatry.2019.1189","article-title":"Efficacy of Esketamine nasal spray plus Oral antidepressant treatment for relapse prevention in patients with treatment-resistant depression: a randomized clinical trial","volume":"76","author":"Daly","year":"2019","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.jad.2026.121970_bb0145","doi-asserted-by":"crossref","DOI":"10.1016\/j.psychres.2023.115133","article-title":"Real world effectiveness of repeated ketamine infusions for treatment-resistant depression with comorbid borderline personality disorder","volume":"323","author":"Danayan","year":"2023","journal-title":"Psychiatry Res."},{"key":"10.1016\/j.jad.2026.121970_bb0150","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.jad.2023.12.038","article-title":"The rapid antidepressant effectiveness of repeated dose of intravenous ketamine and intranasal esketamine: a post-hoc analysis of pooled real-world data","volume":"348","author":"d\u2019Andrea","year":"2024","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.jad.2026.121970_bb0155","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.jad.2023.02.152","article-title":"Efficacy and adverse effects of ketamine versus electroconvulsive therapy for major depressive disorder: a systematic review and meta-analysis","volume":"330","author":"de A. Simoes Moreira","year":"2023","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.jad.2026.121970_bb0160","article-title":"Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder","volume":"9","author":"Dean","year":"2021","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.jad.2026.121970_bb0165","article-title":"Ketamine and other glutamate receptor modulators for depression in adults with bipolar disorder","volume":"10","author":"Dean","year":"2021","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.jad.2026.121970_bb0170","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1038\/clpt.1984.235","article-title":"Ketamine kinetics in unmedicated and diazepam-premedicated subjects","volume":"36","author":"Domino","year":"1984","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.jad.2026.121970_bb0175","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1080\/02791072.2019.1587556","article-title":"Ketamine assisted psychotherapy (KAP): patient demographics, clinical data and outcomes in three large practices administering ketamine with psychotherapy","volume":"51","author":"Dore","year":"2019","journal-title":"J. Psychoactive Drugs"},{"key":"10.1016\/j.jad.2026.121970_bb0180","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.2147\/JPR.S360733","article-title":"Ketamine assisted psychotherapy: a systematic narrative review of the literature","volume":"15","author":"Drozdz","year":"2022","journal-title":"J. Pain Res."},{"key":"10.1016\/j.jad.2026.121970_bb7000","first-page":"1","article-title":"Ketamine for acute and chronic pain: beyond anaesthesia","author":"Duong","year":"2026","journal-title":"Pain Manag."},{"key":"10.1016\/j.jad.2026.121970_bb0185","first-page":"644","article-title":"OCEBM levels of evidence system","volume":"68","author":"Durieux","year":"2013","journal-title":"Rev. Med. Liege"},{"key":"10.1016\/j.jad.2026.121970_bb0190","doi-asserted-by":"crossref","first-page":"352","DOI":"10.3390\/neurolint15010023","article-title":"Ketamine evolving clinical roles and potential effects with cognitive, motor and driving ability","volume":"15","author":"Edinoff","year":"2023","journal-title":"Neurol. Int."},{"key":"10.1016\/j.jad.2026.121970_bb0195","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1111\/j.1460-9592.2011.03606.x","article-title":"Children on phenobarbital monotherapy requires more sedatives during MRI","volume":"21","author":"Eker","year":"2011","journal-title":"Paediatr. Anaesth."},{"key":"10.1016\/j.jad.2026.121970_bb0200","doi-asserted-by":"crossref","DOI":"10.1177\/20451253251394127","article-title":"Intravenous ketamine versus esketamine for depression: a systematic review and meta-analysis","volume":"15","author":"Elmosalamy","year":"2025","journal-title":"Ther. Adv. Psychopharmacol."},{"key":"10.1016\/j.jad.2026.121970_bb0205","doi-asserted-by":"crossref","DOI":"10.1177\/20451253231202723","article-title":"Ketamine for bipolar depression: an updated systematic review","volume":"13","author":"Fancy","year":"2023","journal-title":"Ther. Adv. Psychopharmacol."},{"key":"10.1016\/j.jad.2026.121970_bb0210","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1038\/s41380-018-0256-5","article-title":"Double-blind, placebo-controlled, dose-ranging trial of intravenous ketamine as adjunctive therapy in treatment-resistant depression (TRD)","volume":"25","author":"Fava","year":"2020","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.jad.2026.121970_bb0215","series-title":"FDA Warns Patients and Health Care Providers about Potential Risks Associated with Compounded Ketamine Products, Including Oral Formulations, for the Treatment of Psychiatric Disorders","author":"FDA","year":"2023"},{"key":"10.1016\/j.jad.2026.121970_bb0220","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.jad.2023.03.083","article-title":"The need for establishing best practices and gold standards in psychedelic medicine","volume":"332","author":"Feduccia","year":"2023","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.jad.2026.121970_bb0225","doi-asserted-by":"crossref","DOI":"10.4088\/JCP.22m14491","article-title":"Effect of concomitant benzodiazepines on the antidepressant effects of ketamine: findings from the RAPID intravenous ketamine study","volume":"84","author":"Feeney","year":"2022","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.jad.2026.121970_bb0230","doi-asserted-by":"crossref","DOI":"10.3390\/ph13070151","article-title":"Safety of repeated administration of parenteral ketamine for depression","volume":"13","author":"Feifel","year":"2020","journal-title":"Pharmaceuticals (Basel)"},{"key":"10.1016\/j.jad.2026.121970_bb0235","doi-asserted-by":"crossref","DOI":"10.1016\/j.pnpbp.2024.111152","article-title":"Efficacy of single and repeated ketamine administration for suicidal ideation in adults with psychiatric disorders: a meta-analysis","volume":"136","author":"Feng","year":"2025","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.jad.2026.121970_bb0240","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1038\/s41386-023-01540-4","article-title":"A pilot randomized controlled trial of ketamine in borderline personality disorder","volume":"48","author":"Fineberg","year":"2023","journal-title":"Neuropsychopharmacol"},{"key":"10.1016\/j.jad.2026.121970_bb0245","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1176\/appi.ajp.20240515","article-title":"Esketamine treatment for depression in adults: a PRISMA systematic review and Meta-analysis","volume":"182","author":"Fountoulakis","year":"2025","journal-title":"AJP"},{"key":"10.1016\/j.jad.2026.121970_bb0255","doi-asserted-by":"crossref","DOI":"10.3389\/fnhum.2023.1200393","article-title":"Imprinting: expanding the extra-pharmacological model of psychedelic drug action to incorporate delayed influences of sets and settings","volume":"17","author":"Garel","year":"2023","journal-title":"Front. Hum. Neurosci."},{"key":"10.1016\/j.jad.2026.121970_bb0250","article-title":"The Montreal model: an integrative biomedical-psychedelic approach to ketamine for severe treatment-resistant depression","volume":"14","author":"Garel","year":"2023","journal-title":"Front. Psychol."},{"key":"10.1016\/j.jad.2026.121970_bb0260","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1007\/s40501-025-00346-z","article-title":"Ketamine-assisted psychotherapy for treatment-resistant depression: a systematic review","volume":"12","author":"Gomes","year":"2025","journal-title":"Curr. Treat. Options Psychiatry"},{"key":"10.1016\/j.jad.2026.121970_bb0265","doi-asserted-by":"crossref","DOI":"10.1177\/2045125320981498","article-title":"Apnea during slow sub-anaesthetic infusion of intravenous ketamine for treatment-resistant depression","volume":"10","author":"G\u00f3mez-Revuelta","year":"2020","journal-title":"Ther. Adv. Psychopharmacol."},{"key":"10.1016\/j.jad.2026.121970_bb0270","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1097\/YIC.0000000000000363","article-title":"Adjunctive music improves the tolerability of intravenous ketamine for bipolar depression","volume":"36","author":"Greenway","year":"2021","journal-title":"Int. Clin. Psychopharmacol."},{"key":"10.1016\/j.jad.2026.121970_bb0275","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1017\/S1041610220000903","article-title":"A systematic review of ketamine for the treatment of depression among older adults","volume":"33","author":"Gupta","year":"2021","journal-title":"Int. Psychogeriatr."},{"key":"10.1016\/j.jad.2026.121970_bb0280","doi-asserted-by":"crossref","DOI":"10.1016\/j.psychres.2024.115865","article-title":"IV low dose ketamine infusions for treatment resistant depression: results from a five-year study at a free public clinic in an academic hospital","volume":"335","author":"Gutierrez","year":"2024","journal-title":"Psychiatry Res."},{"key":"10.1016\/j.jad.2026.121970_bb0285","doi-asserted-by":"crossref","first-page":"S210","DOI":"10.1016\/j.biopsych.2024.02.770","article-title":"271. Maintenance ketamine infusions demonstrate sustained antidepressant efficacy in a real-world treatment-resistant unipolar and bipolar depression sample","volume":"95","author":"Haikazian","year":"2024","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.jad.2026.121970_bb0290","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1503\/cmaj.112120","article-title":"Informed consent for clinical treatment","volume":"184","author":"Hall","year":"2012","journal-title":"CMAJ"},{"key":"10.1016\/j.jad.2026.121970_bb0295","first-page":"320","article-title":"Regulating ketamine use in psychiatry","volume":"51","author":"Harding","year":"2023","journal-title":"J. Am. Acad. Psychiatry Law"},{"key":"10.1016\/j.jad.2026.121970_bb0300","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/j.jad.2023.04.141","article-title":"The effects of ketamine on symptoms of depression and anxiety in real-world care settings: a retrospective controlled analysis","volume":"335","author":"Hietamies","year":"2023","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.jad.2026.121970_bb6000","doi-asserted-by":"crossref","first-page":"180","DOI":"10.29173\/jchla29801","article-title":"JBI Critical appraisal checklist for systematic reviews and research syntheses","volume":"45","author":"Hilton","year":"2024","journal-title":"J. Can. Health Libr. Assoc."},{"key":"10.1016\/j.jad.2026.121970_bb0305","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1192\/bjp.2021.163","article-title":"Esketamine: uncertain safety and efficacy data in depression","volume":"219","author":"Horowitz","year":"2021","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.jad.2026.121970_bb0310","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.jad.2023.10.120","article-title":"A systematic review of the incidence of medical serious adverse events in sub-anesthetic ketamine treatment of psychiatric disorders","volume":"345","author":"Hovda","year":"2024","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.jad.2026.121970_bb0315","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1097\/00000542-199503000-00005","article-title":"Additive interactions between propofol and ketamine when used for anesthesia induction in female patients","volume":"82","author":"Hui","year":"1995","journal-title":"Anesthesiology"},{"key":"10.1016\/j.jad.2026.121970_bb0320","doi-asserted-by":"crossref","DOI":"10.1177\/00048674251333577","article-title":"Royal Australian and New Zealand College of Psychiatrists professional practice guidelines for the use of ketamine in psychiatric practice","author":"Hussain","year":"2025","journal-title":"Aust. N. Z. J. Psychiatry"},{"key":"10.1016\/j.jad.2026.121970_bb0325","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1177\/02698811241303597","article-title":"Is there a risk of addiction to ketamine during the treatment of depression? A systematic review of available literature","volume":"39","author":"Ingrosso","year":"2025","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.jad.2026.121970_bb0330","author":"Janssen Pharmaceuticals"},{"key":"10.1016\/j.jad.2026.121970_bb0335","doi-asserted-by":"crossref","DOI":"10.1192\/bjo.2024.62","article-title":"Guidelines for ketamine use in clinical psychiatry practice","volume":"10","author":"Jelen","year":"2024","journal-title":"BJPsych Open"},{"key":"10.1016\/j.jad.2026.121970_bb0340","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1001\/jamapsychiatry.2025.3019","article-title":"Serial ketamine infusions as adjunctive therapy to inpatient Care for Depression","volume":"82","author":"Jelovac","year":"2025","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.jad.2026.121970_bb0345","doi-asserted-by":"crossref","DOI":"10.1177\/03000605241258473","article-title":"Is there evidence for using ketamine among individuals with dementia?","volume":"52","author":"Kapoor","year":"2024","journal-title":"J. Int. Med. Res."},{"key":"10.1016\/j.jad.2026.121970_bb0350","doi-asserted-by":"crossref","first-page":"2283","DOI":"10.3390\/biomedicines12102283","article-title":"Ketamine, Esketamine, and Arketamine: their mechanisms of action and applications in the treatment of depression and alleviation of depressive symptoms","volume":"12","author":"Kawczak","year":"2024","journal-title":"Biomedicines"},{"key":"10.1016\/j.jad.2026.121970_bb0355","author":"Ketalar\u00ae"},{"key":"10.1016\/j.jad.2026.121970_bb0360","doi-asserted-by":"crossref","DOI":"10.1016\/j.neubiorev.2024.105693","article-title":"Exploring the impact of music on response to ketamine\/esketamine: a scoping review","volume":"162","author":"Kheirkhah","year":"2024","journal-title":"Neurosci. Biobehav. Rev."},{"key":"10.1016\/j.jad.2026.121970_bb0365","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1007\/s43440-020-00097-z","article-title":"Efficacy of single and repeated administration of ketamine in unipolar and bipolar depression: a meta-analysis of randomized clinical trials","volume":"72","author":"Kryst","year":"2020","journal-title":"Pharmacol. Rep."},{"key":"10.1016\/j.jad.2026.121970_bb0370","first-page":"1","article-title":"Ketamine for the treatment of psychiatric disorders: a systematic review and meta-analysis","author":"Kwan","year":"2024","journal-title":"CNS Spectr."},{"key":"10.1016\/j.jad.2026.121970_bb0375","doi-asserted-by":"crossref","DOI":"10.1016\/j.psychres.2021.114231","article-title":"Ketamine for psychotic depression: an overview of the glutamatergic system and ketamine\u2019s mechanisms associated with antidepressant and psychotomimetic effects","volume":"306","author":"Le","year":"2021","journal-title":"Psychiatry Res."},{"key":"10.1016\/j.jad.2026.121970_bb0380","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1007\/s00406-024-01945-2","article-title":"Arketamine: a scoping review of its use in humans","volume":"275","author":"Leal","year":"2025","journal-title":"Eur. Arch. Psychiatry Clin. Neurosci."},{"key":"10.1016\/j.jad.2026.121970_bb0385","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.euroneuro.2022.02.004","article-title":"Ketamine and esketamine for crisis management in patients with depression: why, whom, and how?","volume":"57","author":"Lengvenyte","year":"2022","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.jad.2026.121970_bb0390","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1007\/s00406-024-01920-x","article-title":"Efficacy of racemic ketamine or esketamine monotherapy for reducing suicidal ideation in uni- or bipolar depression: a systematic review and meta-analysis","volume":"275","author":"Li","year":"2025","journal-title":"Eur. Arch. Psychiatry Clin. Neurosci."},{"key":"10.1016\/j.jad.2026.121970_bb0395","doi-asserted-by":"crossref","DOI":"10.1016\/j.psychres.2025.116647","article-title":"Outcomes of patients receiving interventional psychiatric procedures in a large integrated healthcare system - ScienceDirect","volume":"351","author":"Li","year":"2025","journal-title":"Psychiatry Res."},{"key":"10.1016\/j.jad.2026.121970_bb0400","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1176\/appi.ajp.20250276","article-title":"Ketamine for depression, but at what cost? A review of ketamine\u2019s neurotoxic effects from preclinical and human studies","volume":"182","author":"Li","year":"2025","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.jad.2026.121970_bb0405","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1097\/00000542-197509000-00007","article-title":"Interaction between sedative premedicants and ketamine in man in isolated perfused rat livers","volume":"43","author":"Lo","year":"1975","journal-title":"Anesthesiology"},{"key":"10.1016\/j.jad.2026.121970_bb0410","doi-asserted-by":"crossref","DOI":"10.1007\/s11126-025-10121-1","article-title":"Comparative efficacy and safety of ketamine versus electroconvulsive therapy in major depressive disorder: a Meta-analysis of randomized controlled trials","author":"Ma","year":"2025","journal-title":"Psychiatry Q."},{"key":"10.1016\/j.jad.2026.121970_bb0415","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/j.jad.2020.09.007","article-title":"A systematic review and meta-analysis of the efficacy of intravenous ketamine infusion for treatment resistant depression: January 2009 - January 2019","volume":"277","author":"Marcantoni","year":"2020","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.jad.2026.121970_bb0420","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1001\/jamapsychiatry.2024.0184","article-title":"Essentials of informed consent to psychedelic medicine","volume":"81","author":"Marks","year":"2024","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.jad.2026.121970_bb0425","doi-asserted-by":"crossref","first-page":"e75","DOI":"10.1016\/j.biopsych.2019.02.008","article-title":"Concurrent use of buprenorphine, methadone, or naltrexone does not inhibit ketamine\u2019s antidepressant activity","volume":"85","author":"Marton","year":"2019","journal-title":"Biol. Psychiatry"},{"issue":"8","key":"10.1016\/j.jad.2026.121970_bb0430","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1080\/09540261.2024.2406329","article-title":"Learning how to make use of dissociative therapies","volume":"36","author":"Mathai","year":"2024","journal-title":"Int. Rev. Psychiatry"},{"key":"10.1016\/j.jad.2026.121970_bb0435","series-title":"Ketamine and Esketamine","author":"Mathai","year":"2024"},{"key":"10.1016\/j.jad.2026.121970_bb0440","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.jad.2019.12.023","article-title":"The relationship between subjective effects induced by a single dose of ketamine and treatment response in patients with major depressive disorder: a systematic review","volume":"264","author":"Mathai","year":"2020","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.jad.2026.121970_bb0445","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1089\/cap.2021.0078","article-title":"Parental attitudes toward use of ketamine in adolescent mood disorders and suicidality","volume":"31","author":"Mathai","year":"2021","journal-title":"J. Child Adolesc. Psychopharmacol."},{"key":"10.1016\/j.jad.2026.121970_bb0450","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.jad.2022.06.036","article-title":"Mapping consent practices for outpatient psychiatric use of ketamine","volume":"312","author":"Mathai","year":"2022","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.jad.2026.121970_bb0460","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1192\/bjp.2022.58","article-title":"The conundrum of therapeutic intoxication","volume":"221","author":"Mathai","year":"2022","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.jad.2026.121970_bb0455","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyg.2022.868103","article-title":"Toward synergies of ketamine and psychotherapy","volume":"13","author":"Mathai","year":"2022","journal-title":"Front. Psychol."},{"key":"10.1016\/j.jad.2026.121970_bb0465","doi-asserted-by":"crossref","DOI":"10.1089\/psymed.2023.0035","article-title":"Double-blind comparison of the two hallucinogens dextromethorphan and psilocybin: experience-dependent and enduring psychological effects in healthy volunteers","author":"Mathai","year":"2023","journal-title":"Psychedelic Medicine."},{"key":"10.1016\/j.jad.2026.121970_bb0470","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.jad.2024.05.131","article-title":"At-home, telehealth-supported ketamine treatment for depression: findings from longitudinal, machine learning and symptom network analysis of real-world data","volume":"361","author":"Mathai","year":"2024","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.jad.2026.121970_bb0475","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.jad.2021.12.097","article-title":"A retrospective analysis of ketamine intravenous therapy for depression in real-world care settings","volume":"301","author":"McInnes","year":"2022","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.jad.2026.121970_bb0480","doi-asserted-by":"crossref","DOI":"10.1016\/j.psychres.2025.116689","article-title":"A retrospective analysis of ketamine intravenous therapy for post-traumatic stress disorder in real-world care settings","author":"McInnes","year":"2025","journal-title":"Psychiatry Res."},{"key":"10.1016\/j.jad.2026.121970_bb0485","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1016\/j.jad.2020.06.050","article-title":"The effect of intravenous, intranasal, and oral ketamine in mood disorders: a meta-analysis","volume":"276","author":"McIntyre","year":"2020","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.jad.2026.121970_bb0490","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1111\/bdi.12941","article-title":"The effectiveness of ketamine on anxiety, irritability, and agitation: implications for treating mixed features in adults with major depressive or bipolar disorder","volume":"22","author":"McIntyre","year":"2020","journal-title":"Bipolar Disord."},{"key":"10.1016\/j.jad.2026.121970_bb0495","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1016\/j.jad.2020.05.088","article-title":"The effectiveness of repeated intravenous ketamine on depressive symptoms, suicidal ideation and functional disability in adults with major depressive disorder and bipolar disorder: results from the Canadian rapid treatment Center of Excellence","volume":"274","author":"McIntyre","year":"2020","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.jad.2026.121970_bb0500","doi-asserted-by":"crossref","DOI":"10.1176\/appi.ajp.2020.20081251","article-title":"Synthesizing the evidence for ketamine and esketamine in treatment-resistant depression: an international expert opinion on the available evidence and implementation","author":"McIntyre","year":"2021","journal-title":"AJP"},{"key":"10.1016\/j.jad.2026.121970_bb0505","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1002\/wps.21120","article-title":"Treatment-resistant depression: definition, prevalence, detection, management, and investigational interventions","volume":"22","author":"McIntyre","year":"2023","journal-title":"World Psychiatry"},{"key":"10.1016\/j.jad.2026.121970_bb0510","doi-asserted-by":"crossref","first-page":"2795","DOI":"10.1007\/s12325-021-01732-8","article-title":"Strategies to prolong ketamine\u2019s efficacy in adults with treatment-resistant depression","volume":"38","author":"McMullen","year":"2021","journal-title":"Adv. Ther."},{"key":"10.1016\/j.jad.2026.121970_bb0515","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/j.jpsychires.2022.10.062","article-title":"Does route of administration affect antidepressant efficacy of ketamine? A meta-analysis of double-blind randomized controlled trials comparing intravenous and intranasal administration","volume":"156","author":"Meiering","year":"2022","journal-title":"J. Psychiatr. Res."},{"key":"10.1016\/j.jad.2026.121970_bb0520","doi-asserted-by":"crossref","DOI":"10.4088\/JCP.25m15789","article-title":"Comparative effects of repeated ketamine infusion versus intranasal Esketamine in patients with treatment-resistant depression: a retrospective chart review","volume":"86","author":"Meisner","year":"2025","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.jad.2026.121970_bb0525","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1001\/jamapsychiatry.2023.0562","article-title":"Ketamine vs electroconvulsive therapy for major depressive episode: a systematic review and Meta-analysis","volume":"80","author":"Menon","year":"2023","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.jad.2026.121970_bb0530","series-title":"Psychodynamic Psychopharmacology: Caring for the Treatment-Resistant Patient","author":"Mintz","year":"2022"},{"key":"10.1016\/j.jad.2026.121970_bb0535","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1111\/cns.12099","article-title":"Ketamine pharmacology: an update (pharmacodynamics and molecular aspects, recent findings)","volume":"19","author":"Mion","year":"2013","journal-title":"CNS Neurosci. Ther."},{"key":"10.1016\/j.jad.2026.121970_bb0540","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s42077-022-00222-5","article-title":"Safety and efficacy of ketamine-dexmedetomidine combination versus dexmedetomidine alone in cirrhotic patients undergoing upper gastrointestinal endoscopy: a prospective controlled clinical trial","volume":"14","author":"Mohamed","year":"2022","journal-title":"Ain-Shams J. Anesthesiol."},{"key":"10.1016\/j.jad.2026.121970_bb0545","article-title":"An integrative approach to ketamine therapy may enhance multiple dimensions of efficacy: improving therapeutic outcomes with treatment resistant depression","volume":"12","author":"Muscat","year":"2021","journal-title":"Front. Psychol."},{"key":"10.1016\/j.jad.2026.121970_bb0550","doi-asserted-by":"crossref","DOI":"10.1038\/s41398-024-03031-6","article-title":"Depression clinical trials worldwide: a systematic analysis of the ICTRP and comparison with ClinicalTrials.gov","volume":"14","author":"Namiot","year":"2024","journal-title":"Transl. Psychiatry"},{"key":"10.1016\/j.jad.2026.121970_bb0555","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2023.102127","article-title":"Ketamine for the treatment of major depression: a systematic review and meta-analysis","volume":"62","author":"Nikolin","year":"2023","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.jad.2026.121970_bb0560","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1038\/s41398-026-03806-z","article-title":"Time matters for metas: a systematic review and meta-analysis of ect vs ketamine for depression incorporating time","volume":"16","author":"Nikolin","year":"2026","journal-title":"Transl. Psychiatry"},{"key":"10.1016\/j.jad.2026.121970_bb0570","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.3390\/brainsci13121672","article-title":"An update on the efficacy of single and serial intravenous ketamine infusions and Esketamine for bipolar depression: a systematic review and Meta-analysis","volume":"13","author":"Nunez","year":"2023","journal-title":"Brain Sci."},{"key":"10.1016\/j.jad.2026.121970_bb0575","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.jad.2021.03.006","article-title":"Distinct trajectories of antidepressant response to intravenous ketamine","volume":"286","author":"O\u2019Brien","year":"2021","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.jad.2026.121970_bb0580","doi-asserted-by":"crossref","DOI":"10.4088\/JCP.21m14336","article-title":"Clinical effectiveness of intravenous racemic ketamine infusions in a large community sample of patients with treatment-resistant depression, suicidal ideation, and generalized anxiety symptoms: a retrospective chart review","volume":"83","author":"Oliver","year":"2022","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.jad.2026.121970_bb0585","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.jpsychires.2024.11.010","article-title":"Intranasal esketamine for patients with major depressive disorder: a systematic review and meta-analysis","volume":"180","author":"Oraee","year":"2024","journal-title":"J. Psychiatr. Res."},{"key":"10.1016\/j.jad.2026.121970_bb0590","doi-asserted-by":"crossref","DOI":"10.4088\/JCP.24m15293","article-title":"Safe ketamine use and pregnancy: a Nationwide survey and retrospective review of informed consent, counseling, and testing practices","volume":"85","author":"Pacilio","year":"2024","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.jad.2026.121970_bb0595","doi-asserted-by":"crossref","DOI":"10.4088\/JCP.25m15809","article-title":"Outpatient ketamine prescribing practices in psychiatry in the United States: a nationwide survey study","volume":"86","author":"Pacilio","year":"2025","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.jad.2026.121970_bb0600","doi-asserted-by":"crossref","DOI":"10.1016\/j.psychres.2024.115994","article-title":"Ketamine versus electroconvulsive therapy for major depressive episode: an updated systematic review and non-inferiority meta-analysis","volume":"339","author":"Petrucci","year":"2024","journal-title":"Psychiatry Res."},{"key":"10.1016\/j.jad.2026.121970_bb0605","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1001\/jamapsychiatry.2022.3352","article-title":"Efficacy and safety of ketamine vs electroconvulsive therapy among patients with major depressive episode: a systematic review and Meta-analysis","volume":"79","author":"Rhee","year":"2022","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.jad.2026.121970_bb0610","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1177\/154733251903100411","article-title":"High-dose ketamine infusion for the treatment of posttraumatic stress disorder in combat veterans","volume":"31","author":"Ross","year":"2019","journal-title":"Ann. Clin. Psychiatry"},{"key":"10.1016\/j.jad.2026.121970_bb0615","article-title":"Ethical guidelines for ketamine clinicians","volume":"2","author":"Ryan","year":"2020","journal-title":"The journal of psychedelic Psychiatry"},{"key":"10.1016\/j.jad.2026.121970_bb0620","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1038\/s41386-024-02044-5","article-title":"Relative effectiveness of antidepressant treatments in treatment-resistant depression: a systematic review and network meta-analysis of randomized controlled trials","volume":"50","author":"Saelens","year":"2025","journal-title":"Neuropsychopharmacol"},{"key":"10.1016\/j.jad.2026.121970_bb0625","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/j.jad.2020.07.089","article-title":"Long-term outcome in outpatients with depression treated with acute and maintenance intravenous ketamine: a retrospective chart review","volume":"276","author":"Sakurai","year":"2020","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.jad.2026.121970_bb0630","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.jad.2019.09.017","article-title":"Time to relapse after a single administration of intravenous ketamine augmentation in unipolar treatment-resistant depression","volume":"260","author":"Salloum","year":"2020","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.jad.2026.121970_bb0635","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1001\/jamapsychiatry.2017.0080","article-title":"A consensus statement on the use of ketamine in the treatment of mood disorders","volume":"74","author":"Sanacora","year":"2017","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.jad.2026.121970_bb0640","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1176\/appi.ajp.20240655","article-title":"Real-world safety of Esketamine nasal spray: a comprehensive analysis almost 5 years after first approval","volume":"182","author":"Sanacora","year":"2025","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.jad.2026.121970_bb0645","doi-asserted-by":"crossref","first-page":"S176","DOI":"10.1016\/j.biopsych.2025.02.433","article-title":"196. Lamotrigine is not associated with differential clinical outcomes in a real-world sample of patients with unipolar depression receiving ketamine\/Esketamine","volume":"97","author":"Santucci","year":"2025","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.jad.2026.121970_bb9000","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s40545-020-00282-8","article-title":"Repurposing existing drugs for new uses: a cohort study of the frequency of FDA-granted new indication exclusivities since 1997","volume":"14","author":"Sahragardjoonegani","year":"2021","journal-title":"J. Pharm. Policy Pract."},{"key":"10.1016\/j.jad.2026.121970_bb0650","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1038\/s41386-023-01647-8","article-title":"The why, when, where, how, and so what of so-called rapidly acting antidepressants","volume":"49","author":"Schatzberg","year":"2024","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.jad.2026.121970_bb0655","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.jad.2024.03.137","article-title":"Efficacy of intravenous ketamine and intranasal esketamine with dose escalation for major depression: a systematic review and meta-analysis","volume":"356","author":"Seshadri","year":"2024","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.jad.2026.121970_bb0660","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajp.2023.103720","article-title":"Ketamine versus electroconvulsive therapy for treatment-resistant depression: an updated meta-analysis of randomized clinical trials","volume":"88","author":"Shafiee","year":"2023","journal-title":"Asian J. Psychiatr."},{"key":"10.1016\/j.jad.2026.121970_bb0665","doi-asserted-by":"crossref","DOI":"10.1002\/brb3.71255","article-title":"Comparative efficacy and safety of ketamine versus midazolam for suicidality: a GRADE-assessed systematic review and Meta-analysis of randomized controlled trials","volume":"16","author":"Shah","year":"2026","journal-title":"Brain Behav."},{"key":"10.1016\/j.jad.2026.121970_bb0670","series-title":"Informed Consent, in: StatPearls","author":"Shah","year":"2021"},{"key":"10.1016\/j.jad.2026.121970_bb0675","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1038\/s41398-024-02973-1","article-title":"A meta-analysis of the effects of ketamine on suicidal ideation in depression patients","volume":"14","author":"Shen","year":"2024","journal-title":"Transl. Psychiatry"},{"key":"10.1016\/j.jad.2026.121970_bb0680","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S2215-0366(17)30272-9","article-title":"Side-effects associated with ketamine use in depression: a systematic review","volume":"5","author":"Short","year":"2018","journal-title":"Lancet Psychiatry"},{"key":"10.1016\/j.jad.2026.121970_bb0685","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/j.jad.2020.01.120","article-title":"Development of the ketamine side effect tool (KSET)","volume":"266","author":"Short","year":"2020","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.jad.2026.121970_bb0690","doi-asserted-by":"crossref","DOI":"10.1016\/j.jad.2025.120466","article-title":"Oral ketamine for the treatment of major depressive and bipolar disorder, a randomized controlled trial and meta-analysis","volume":"394","author":"Silberbauer","year":"2026","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.jad.2026.121970_bb0695","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1176\/appi.ajp.2015.1720501","article-title":"The American Psychiatric Association practice guidelines for the psychiatric evaluation of adults","volume":"172","author":"Silverman","year":"2015","journal-title":"AJP"},{"key":"10.1016\/j.jad.2026.121970_bb0700","doi-asserted-by":"crossref","DOI":"10.4088\/JCP.22m14548","article-title":"Comparative effectiveness of intravenous ketamine and intranasal esketamine in clinical practice among patients with treatment-refractory depression: an observational study","volume":"84","author":"Singh","year":"2023","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.jad.2026.121970_bb0705","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/S2215-0366(17)30102-5","article-title":"Ketamine treatment for depression: opportunities for clinical innovation and ethical foresight","volume":"4","author":"Singh","year":"2017","journal-title":"Lancet Psychiatry"},{"key":"10.1016\/j.jad.2026.121970_bb0710","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1176\/appi.ajp.2016.16010037","article-title":"A double-blind, randomized, placebo-controlled, dose-frequency study of intravenous ketamine in patients with treatment-resistant depression","volume":"173","author":"Singh","year":"2016","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.jad.2026.121970_bb0715","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1016\/S2215-0366(22)00317-0","article-title":"Maintenance ketamine treatment for depression: a systematic review of efficacy, safety, and tolerability","volume":"9","author":"Smith-Apeldoorn","year":"2022","journal-title":"Lancet Psychiatry"},{"key":"10.1016\/j.jad.2026.121970_bb0720","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1080\/13651501.2025.2576205","article-title":"A systematic review and meta-analysis of the efficacy of ketamine compared to electroconvulsive therapy for treatment-resistant depression","volume":"30","author":"Song","year":"2026","journal-title":"Int. J. Psychiatry Clin. Pract."},{"key":"10.1016\/j.jad.2026.121970_bb0725","series-title":"SPRAVATO\u00ae HCP","author":"SPRAVATO\u00ae (esketamine)","year":"2018"},{"key":"10.1016\/j.jad.2026.121970_bb0730","series-title":"Standards of Practice in the Therapeutic Use of SUBANESTHETIC Ketamine","author":"Sullivan","year":"2020"},{"key":"10.1016\/j.jad.2026.121970_bb0735","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1177\/0706743720970860","volume":"66","author":"Swainson","year":"2021","journal-title":"Can. J. Psychiatr."},{"key":"10.1016\/j.jad.2026.121970_bb0740","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1097\/JCP.0000000000001946","article-title":"Ketamine\u2019s altered states meta-analysis: the relationship between psychomimetic and clinical effects with focus in depression","volume":"45","author":"Tavares","year":"2025","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.jad.2026.121970_bb0745","article-title":"Comparative antidepressant effects and safety of intravenous racemic ketamine, psilocybin and theta burst stimulation for major depressive disorder: a systematic review and network meta-analyses of randomized controlled trials","volume":"3","author":"Terao","year":"2024","journal-title":"PCN Rep"},{"key":"10.1016\/j.jad.2026.121970_bb0750","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.jad.2023.11.023","article-title":"Comparative efficacy, tolerability and acceptability of intravenous racemic ketamine with intranasal esketamine, aripiprazole and lithium as augmentative treatments for treatment-resistant unipolar depression: a systematic review and network meta-analysis","volume":"346","author":"Terao","year":"2024","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.jad.2026.121970_bb0755","series-title":"Ketamine for adults with substance use disorders: rapid review, CADTH health technology review","author":"Tran","year":"2024"},{"key":"10.1016\/j.jad.2026.121970_bb0760","doi-asserted-by":"crossref","DOI":"10.1111\/inm.13425","article-title":"How do people who undergo ketamine treatment for a psychiatric problem subjectively experience this intervention? A Meta-synthesis of qualitative studies","volume":"34","author":"Trimmel","year":"2025","journal-title":"Int. J. Ment. Health Nurs."},{"key":"10.1016\/j.jad.2026.121970_bb0770","doi-asserted-by":"crossref","DOI":"10.4088\/JCP.20r13459","article-title":"Ketamine treatment for depression in patients with a history of psychosis or current psychotic symptoms: a systematic review","volume":"82","author":"Veraart","year":"2021","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.jad.2026.121970_bb0765","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1093\/ijnp\/pyab039","article-title":"Pharmacodynamic interactions between ketamine and psychiatric medications used in the treatment of depression: a systematic review","volume":"24","author":"Veraart","year":"2021","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.jad.2026.121970_bb0775","series-title":"Intravenous Ketamine for Treatment Resistant Depression","author":"VHA Office of Integrated Veteran Care","year":"2025"},{"key":"10.1016\/j.jad.2026.121970_bb0780","doi-asserted-by":"crossref","DOI":"10.4088\/JCP.19m12891","article-title":"Esketamine nasal spray plus oral antidepressant in patients with treatment-resistant depression: assessment of long-term safety in a phase 3, open-label study (SUSTAIN-2)","volume":"81","author":"Wajs","year":"2020","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.jad.2026.121970_bb0785","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1038\/s41398-024-03027-2","article-title":"Non-improvement predicts subsequent non-response to repeated-dose intravenous ketamine for depression: a re-analysis of a 2-week open-label study in patients with unipolar and bipolar depression","volume":"14","author":"Wang","year":"2024","journal-title":"Transl. Psychiatry"},{"key":"10.1016\/j.jad.2026.121970_bb0790","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1007\/s00228-023-03605-1","article-title":"A systematic review and meta-analysis of the efficacy of ketamine and esketamine on suicidal ideation in treatment-resistant depression","volume":"80","author":"Wang","year":"2024","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.jad.2026.121970_bb0795","doi-asserted-by":"crossref","DOI":"10.1177\/20451253211056743","article-title":"Systematic review and meta-analysis of randomized controlled trials of ketamine in the treatment of refractory anxiety spectrum disorders","volume":"11","author":"Whittaker","year":"2021","journal-title":"Ther Adv Psychopharmacol"},{"key":"10.1016\/j.jad.2026.121970_bb0800","doi-asserted-by":"crossref","DOI":"10.4088\/JCP.17m11731","article-title":"Acute and longer-term outcomes using ketamine as a clinical treatment at the Yale psychiatric hospital","volume":"79","author":"Wilkinson","year":"2018","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.jad.2026.121970_bb0805","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1038\/s41386-019-0317-8","article-title":"Impact of midazolam vs. saline on effect size estimates in controlled trials of ketamine as a rapid-acting antidepressant","volume":"44","author":"Wilkinson","year":"2019","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.jad.2026.121970_bb0810","doi-asserted-by":"crossref","DOI":"10.1001\/jamapsychiatry.2023.4945","article-title":"The rapidly shifting ketamine landscape in the US","author":"Wilkinson","year":"2024","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.jad.2026.121970_bb0815","doi-asserted-by":"crossref","first-page":"645","DOI":"10.3390\/cells11040645","article-title":"Ketamine and lamotrigine combination in psychopharmacology: systematic review","volume":"11","author":"Wilkowska","year":"2022","journal-title":"Cells"},{"key":"10.1016\/j.jad.2026.121970_bb0820","doi-asserted-by":"crossref","DOI":"10.1176\/appi.ajp.2018.18020138","article-title":"Attenuation of antidepressant effects of ketamine by opioid receptor antagonism","author":"Williams","year":"2018","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.jad.2026.121970_bb0825","series-title":"Guidelines for the Personal Use and the Clinical Administration of Ketamine","author":"Wolfson","year":"2025"},{"key":"10.1016\/j.jad.2026.121970_bb0830","article-title":"Ketamine-assisted psychotherapy, psychedelic methodologies, and the impregnable value of the subjective-a new and evolving approach","volume":"15","author":"Wolfson","year":"2024","journal-title":"Front. Psychol."},{"key":"10.1016\/j.jad.2026.121970_bb0835","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1080\/02791072.2022.2101903","article-title":"The pharmacokinetics of ketamine in the breast Milk of lactating women: quantification of ketamine and metabolites","volume":"55","author":"Wolfson","year":"2023","journal-title":"J. Psychoactive Drugs"},{"key":"10.1016\/j.jad.2026.121970_bb8000","series-title":"Guidelines for the Personal Use and The Clinical Administration of Ketamine Safety and Standard of Care - The Expanded Second Edition","author":"Wolfson","year":"2026"},{"key":"10.1016\/j.jad.2026.121970_bb0840","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.jpsychires.2020.12.038","article-title":"The acute antisuicidal effects of single-dose intravenous ketamine and intranasal esketamine in individuals with major depression and bipolar disorders: a systematic review and meta-analysis","volume":"134","author":"Xiong","year":"2021","journal-title":"J. Psychiatr. Res."},{"key":"10.1016\/j.jad.2026.121970_bb0845","article-title":"Intravenous ketamine for depression: a clinical discussion reconsidering best practices in acute hypertension management","volume":"13","author":"Yip","year":"2022","journal-title":"Front. Psychol."},{"key":"10.1016\/j.jad.2026.121970_bb0850","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1038\/s41386-023-01577-5","article-title":"Long-term safety and maintenance of response with esketamine nasal spray in participants with treatment-resistant depression: interim results of the SUSTAIN-3 study","volume":"48","author":"Zaki","year":"2023","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.jad.2026.121970_bb0855","doi-asserted-by":"crossref","first-page":"566","DOI":"10.3390\/healthcare10030566","article-title":"Ketamine in acute brain injury: current opinion following cerebral circulation and electrical activity","volume":"10","author":"Zanza","year":"2022","journal-title":"Healthcare (Basel)"}],"container-title":["Journal of Affective Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165032726008220?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165032726008220?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T00:33:53Z","timestamp":1782261233000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165032726008220"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":174,"alternative-id":["S0165032726008220"],"URL":"https:\/\/doi.org\/10.1016\/j.jad.2026.121970","relation":{},"ISSN":["0165-0327"],"issn-type":[{"value":"0165-0327","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Interdisciplinary, Delphi-driven consensus guidelines on the use of intravenous ketamine infusions for depressive disorders from the American Society of Ketamine Physicians, Psychotherapists, and Practitioners (ASKP3)","name":"articletitle","label":"Article Title"},{"value":"Journal of Affective Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jad.2026.121970","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"121970"}}